To read the full story, subscribe or sign in.

Amgen quits Kyowa Kirin deal, returns rocatinlimab

Feb. 2, 2026

Amgen Inc. quit a development deal with Kyowa Kirin Co. Ltd., returning global rights for rocatinlimab, Kyowa Kirin’s T-cell rebalancing therapy being investigated for moderate to severe atopic dermatitis.

BioWorld Deals and M&A Dermatologic Monoclonal antibody Asia-Pacific Japan

Today's news in brief

BioWorld

BioWorld briefs for May 18, 2026.

ASGCT 2026: Directed evolution in gene therapy

BioWorld

Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...

3D illustration of adeno-associated viruses

ASGCT 2026: Uncovering the mechanisms of AAV toxicity

BioWorld

Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...

Doctor with brain illustration, businessman with dollar sign illustration

Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal

BioWorld

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...

Illustration of tau accumulating in a neuron cell.

Biogen AD drug shows tau, cognition benefit, despite trial miss

BioWorld

Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...